Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2020 Apr 20;26(8):1414–1424. doi: 10.1016/j.bbmt.2020.03.028

Table 4.

Investigator-reported responses

Responses Post-ASCT
(n=57)
Day +100
post-
alloSCT
(n=49)
Best
response
after
alloSCT*
(n=49)
Complete Response (N) (%) 8 (14%) 9 (18%) 18 (37%)
Partial Response (N) (%) 27 (47%) 23 (47%) 18 (37%)
Minimal Response (N) (%) 3 (5%) 2 (4%) 4 (8%)
Stable Disease (N) (%) 14 (25%) 10 (20%) 6 (12%)
Progressive Disease (N) (%) 1 (2%) 3 (6%) 3 (6%)
Missing (N) (%) 5 (9%) 2 (4%) 0
*

prior to initiation of non-protocol therapy